1. Home
  2. Companies
  3. IMU
  4. Material Events

Imugene (ASX:IMU) — Material Events

ASX:IMU · 16 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 16 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
16
Imugene’s Azer-cel Posts 81% Response in CAR T-Naïve Blood Cancer PatientsMedium
Imugene’s Azer-cel Shows 81% Response Rate in CAR T-Naïve Blood Cancer Patients at ASCO 2026
22 May 2026 ·Clinical Trial Update ·85
Imugene’s Azer-cel Hits 82% Response Rate, FDA Clears Path for Pivotal TrialMedium
Imugene reports strong azer-cel trial results, FDA validation, new collaboration, and improved cash flow management
30 Jan 2026 ·Quarterly Activities and Cash Flow Report ·85
Imugene Cuts Losses, Boosts Azer-cel Trial with FDA Nod and $25M RaiseHigh
Imugene narrows loss, advances azer-cel CAR T trials, raises $25M, and secures FDA support
25 Feb 2026 ·Half-Year Report ·85
Imugene’s Azer-cel Trial Hits 81% Response Rate, Raises $25M to Fuel GrowthHigh
Imugene reports 81% response rate in azer-cel trial, raises $25M, and extends cash runway to mid-2027
31 Oct 2025 ·Quarterly Activities and Appendix 4C Cash Report ·85
Imugene’s Azer-cel Shows 100% Response in CLL/SLL, Expands Trial with BTKi ComboMedium
Imugene Reports High Response Rates in Phase 1b azer-cel Trial and Expands Study with BTKi Combination
10 Mar 2026 ·Clinical Trial Update ·85
Imugene and JW Therapeutics Unite to Target Solid Tumors with Novel ‘Mark and Kill’ TherapyMedium
Imugene and JW Therapeutics collaborate on novel CAR-T and oncolytic virus combo for solid tumors
27 Nov 2025 ·Strategic Collaboration Announcement ·85
Imugene Raises $11.1 Million to Fuel Azer-cel’s Clinical MomentumMedium
Imugene raises $11.1 million placement to advance azer-cel after positive clinical data
7 July 2026 ·Capital Raising ·85
Imugene’s Azer-cel Secures FDA Fast Track for Two Blood CancersMedium
Imugene's Azer-cel Granted FDA Fast Track Designation for CLL/SLL and MZL
9 June 2026 ·Regulatory Update ·85
Imugene Secures $20M to Boost Azer-cel Trials and Restructure DebtHigh
Imugene launches $20M capital raise with placement, SPP, and convertible notes amendment
11 Mar 2026 ·Capital Raising ·85
FDA Endorses Imugene’s Azer-cel for Pivotal Phase 3 in Hard-to-Treat LymphomaMedium
FDA Supports Imugene's Azer-cel Phase 3 Registrational Study for DLBCL
8 Dec 2025 ·Regulatory Update ·85
Imugene Unveils $20M Capital Raise to Fuel Azer-cel Clinical Trial PushHigh
Imugene launches $20M equity raise with placement, SPP, options, convertible notes, and warrants to fund clinical trials
17 Mar 2026 ·Capital Raising ·85
Imugene Gains FDA Nod to Advance Azer-cel into Pivotal StudyMedium
Imugene to Host Webinar on Positive FDA Feedback for Azer-cel Therapy Advancement
8 Dec 2025 ·Investor Webinar Announcement ·75
Imugene Expands Azer-cel Trial with BTKi Combo for Resistant Lymphoma PatientsMedium
Imugene doses first patient in BTKi combination cohort of azer-cel Phase 1b trial targeting BTKi-relapsed B-cell malignancies
28 May 2026 ·Clinical Trial Update ·75
Imugene’s Azer-cel Hits Complete Response in BTKi-Resistant Mantle Cell Lymphoma PatientMedium
Imugene reports additional complete response in Phase 1b azer-cel BTKi cohort including first MCL patient
1 July 2026 ·Clinical Trial Update ·75
Imugene Logs Third Response in BTKi-Resistant Lymphoma Cohort Amid CEO DepartureMedium
Imugene reports third response in concurrent BTKi cohort of azer-cel Phase 1b trial
27 July 2026 ·Clinical Trial Update ·75
Imugene’s Azer-cel Shows Complete Response in BTKi-Resistant Follicular Lymphoma PatientMedium
Imugene Reports First Complete Response in BTKi Cohort of Phase 1b Azer-cel Trial
30 June 2026 ·Clinical Trial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.